Functional dependence predicts poorer survival in adults aged 80 and over with NSCLC

Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC

Adjuvant osimertinib delivers sustained long term survival benefit in EGFR mutated NSCLC

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Challenges in doing clinical research in the LATAM region

Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC

Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC

Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC

Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC